Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

61.09
+0.91001.51%
Pre-market: 60.94-0.1500-0.25%07:15 EDT
Volume:18.54M
Turnover:1.14B
Market Cap:123.97B
PE:-13.84
High:63.11
Open:60.45
Low:60.27
Close:60.18
Loading ...

Bristol Myers announces data from Phase 3 POETYK PsA-2

TIPRANKS
·
13 hours ago

Is Bristol-Myers Squibb Company (BMY) The Best Cheap Dividend Stock To Buy Right Now?

Insider Monkey
·
Yesterday

BRIEF-Bristol Myers Squibb Says Sotyktu Well-Tolerated Compared To Placebo And Apremilast

Reuters
·
08 Mar

Bristol Myers Squibb Presents Late-Breaking Data From Phase 3 Poetyk Psa-2 Trial Demonstrating Superiority of Sotyktu (Deucravacitinib) Compared With Placebo in Adults With Psoriatic Arthritis

THOMSON REUTERS
·
08 Mar

Bristol-Myers Squibb Co - Sotyktu Well-Tolerated Compared to Placebo and Apremilast

THOMSON REUTERS
·
08 Mar

Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

Business Wire
·
08 Mar

Bristol Myers Squibb Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
08 Mar

Veteran Investor Touts Meta (META) and Oracle (ORCL)

Insider Monkey
·
08 Mar

Jim Cramer Highlights ‘Multi-Billionaire Dollar’ Catalyst for Bristol-Myers Squibb Company (BMY)

Insider Monkey
·
07 Mar

Bristol-Myers Squibb Says Opdivo With Yervoy Approved in EU to Treat Liver Cancer

MT Newswires Live
·
07 Mar

Bristol Myers Gets Expanded Europe OK of Opdivo/Yervoy Combo in Liver Cancer

Dow Jones
·
07 Mar

BRIEF-Bristol Myers Squibb Receives European Commission Approval For Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab)

Reuters
·
07 Mar

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab) for the First-Line Treatment of Adult Patients With Unresectable or Advanced Hepatocellular Carcinoma

THOMSON REUTERS
·
07 Mar

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Business Wire
·
07 Mar

Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note

Zacks
·
07 Mar

Big Pharma wants to bring back a tax break that could save it $15 billion

Quartz
·
07 Mar